What are analysts'target prices for Cara Therapeutics stock?
9 equities research analysts have issued 1 year target prices for Cara Therapeutics' shares. Their predictions range from $13.36 to $39.00. On average, they expect Cara Therapeutics' share price to reach $26.93 in the next year.
Why did Cara Therapeutics stock crash 43% Thursday?
Shares of Cara Therapeutics ( NASDAQ:CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
Where can I buy shares of Cara?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is the most advanced compound in Cara?
Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary dr
Is CARA a good buy?
Out of 3 analysts, 2 (66.67%) are recommending CARA as a Strong Buy, 1 (33.33%) are recommending CARA as a Buy, 0 (0%) are recommending CARA as a Hold, 0 (0%) are recommending CARA as a Sell, and 0 (0%) are recommending CARA as a Strong Sell.
Why did Cara Therapeutics stock drop?
What happened. Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
Where is Cara Therapeutics located?
Cara Therapeutics is located in Shelton, Connecticut, United States .
What does CARA Therapeutics do?
Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
Will Cara Therapeutics go back up?
Cara Therapeutics Inc (NASDAQ:CARA) The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 27.00, with a high estimate of 30.00 and a low estimate of 13.00. The median estimate represents a +191.89% increase from the last price of 9.25.
Will Korsuva be approved?
FDA approves KORSUVA™ Injection for the Treatment of Pruritus in Hemodialysis Patients. The Food and Drug Administration (FDA) recently approved a new therapeutic injection for the treatment of moderate-to-severe pruritis associated with chronic kidney disease in adults undergoing hemodialysis.
How many employees are at Cara Therapeutics?
Company Growth (employees)Employees (est.) (Feb 2020)67(+22%)Job Openings1Website Visits (Mar 2022)6.5 kRevenue (FY, 2020)$135.1 M(+580%)Share Price (May 2022)$8.31 more row
What is happening with Cara Therapeutics?
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates. Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021.
What is Cara English?
Cara is an Irish feminine given name meaning "friend". It is also an English, German and Italian language feminine given name from the Latin cārus meaning “darling, beloved, dear, loved one”.
Is CARA stock a buy right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are c...
Will Cara Therapeutics' stock price go up in 2022?
4 analysts have issued 12-month target prices for Cara Therapeutics' shares. Their forecasts range from $20.00 to $30.00. On average, they predict...
How has Cara Therapeutics' stock performed in 2022?
Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA shares have decreased by 29.6% and is now trading at $8.5...
Are investors shorting Cara Therapeutics?
Cara Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,350,000 shares, an...
When is Cara Therapeutics' next earnings date?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Cara...
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per...
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the following people: Mr. Christopher A. Posner , Pres, CEO & Director (Age 52, Pay $431.9k) Dr. Der...
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include ChemoCentryx (CCXI) , HUTCHMED (HCM) , Aurinia Pharmaceuticals (AUPH) , Arcus Bios...
What other stocks do shareholders of Cara Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Enterta...
Who sold Cara Therapeutics stock?
When will Cara Therapeutics release its earnings?
Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.
How much does Cara Therapeutics make?
Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Cara Therapeutics.
What is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $597.60 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.
What is the official website of Cara Therapeutics?
is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
What is the P/E ratio of Cara Therapeutics?
The official website for Cara Therapeutics is www.caratherapeutics.com.
Is Cara Therapeutics a buy?
The P/E ratio of Cara Therapeutics is 26.12 , which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.41.
When will the CARA earnings call end?
Cara Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
How many articles has The Fool written on Cara Therapeutics?
CARA earnings call for the period ending June 30, 2021.
Is biotech stock a small cap?
The Fool has written over 200 articles on Cara Therapeutics.
What is Cara Therapeutics?
The biotech stock is being added to an important small-cap index.
What is market cap?
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary dr
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
What happened
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
So what
Shares of Cara Therapeutics ( CARA 0.20% ) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
Now what
With the biotech stock falling so heavily today, you'd think that all the results from the phase 2 trial were really bad. That wasn't entirely the case, though.
